TRANSLATE

The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

The role of AI in the future of MPN bone marrow histopathology

Featured:

Jean-Jacques KiladjianJean-Jacques KiladjianJohn MascarenhasJohn MascarenhasTiziano BarbuiTiziano BarbuiChloé JamesChloé JamesDaniel RoystonDaniel Royston

Dec 4, 2023

Learning objective: After watching this video, learners will be able to cite a new clinical development in myeloproliferative neoplasms.


The MPN Hub invited Daniel Royston, University of Oxford, UK, to give a presentation and chair a discussion on the role of artificial intelligence in the future of myeloproliferative neoplasm bone marrow histopathology. MPN Hub Steering Committee members Jean-Jacques Kiladjian, Tiziano Barbui, Chloe James, and John Mascarenhas joined the discussion.

Royston begins by describing quantitative image analysis in myeloproliferative neoplasms and its potential in clinical trial scenarios. He then outlines results of a quantitative analysis of fibrosis from the zinpentraxin alfa phase II study (NCT01981850). He concludes by highlighting a need for the clinical evaluation and validation of machine learning tools in histopathology.

The role of AI in the future of MPN bone marrow histopathology